Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 2
Low-Dose Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease
The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhib…
Sickle Cell DiseaseAcute Chest Syndrome
Estimated
~$10 – $6,250
University of ChicagoNCT05640271
Observational
Use of Point-of-Care Ultrasound (POCUS) for the Diagnosis of Acute Chest Syndrome in Patients With Sickle Cell Disease
Feasibility and reliability of ultrasound in the inpatient hematology setting.
Acute Chest SyndromeSickle Cell Disease
Estimated
~$10 – $6,250
Indiana UniversityNCT06880679